Chemotherapy remains mainly used for the treatment of acute myeloid leukemia (AML). However, in the past 3 decades limited progress has been achieved in improving the long-term disease-free survival. Therefore the development of more effective drugs for AML represents a high level of priority. F14512 combines an epipodophyllotoxin core targeting topoisomerase II with a spermine moiety introduced as a cell delivery vector. The polyamine moiety facilitates F14512 selective uptake by tumour cells via the polyamine transport system, a machinery overactivated in cancer cells. F14512 has been characterized as a potent drug candidate and is currently in Phase I clinical trials. Here, we demonstrated marked survival benefit and therapeutic efficacy of F14512 treatments in a series of human AML models, established either from AML cell lines or from patient AML samples. Furthermore, we reported in vitro synergistic anti-leukemic effects of F14512 in combination with cytosine arabinoside (Ara-C), doxorubicin, gemcitabine, bortezomib or SAHA. In vivo combination of suboptimal doses of F14512 with Ara-C also resulted in enhanced anti-leukemic activity. We further showed that F14512 triggered both senescence and apoptosis in vivo in primary AML models, but not autophagy. Overall, these results support the clinical development in onco-hematology of this novel promising drug candidate. Leukemia (2013Leukemia ( ) 27, 2139Leukemia ( -2148 doi:10.1038/leu.2013 Keywords: spermine-drug conjugate; targeted cytotoxic agent; antileukemic activity; combination therapy; apoptosis; senescence INTRODUCTION Acute myeloid leukemia (AML) is the most aggressive form of leukemia, resulting from the uncontrolled proliferation of immature myeloid malignant cells.
INTRODUCTION
Acute myeloid leukemia (AML) is the most aggressive form of leukemia, resulting from the uncontrolled proliferation of immature myeloid malignant cells. 1, 2 Despite progress in therapy and supportive care strategies, AML is still treated with various combinations of cytotoxic agents. 1 This approach is effective in younger patients, as they are able to tolerate high concentrations of these agents required to induce complete remission. Approximately 35% of AML patients younger than 60 years exhibit disease-free survival for more than 5 years. 3 However, the majority of AML patients is older (460 years) and can only tolerate low doses of the current cytotoxic agents. 4 This therefore results in only 10% of patients achieving disease-free survival for longer than 5 years. 5 This unfavorable situation leads to a strong need for more effective and better tolerated anti-leukemic therapies.
The use of a lipid vector technology to allow increased drug accumulation in tumor cells, as illustrated by elacytarabine, under investigation in AML, can be cited. 6, 7 Furthermore, an attractive way to improve tumour selectivity of therapeutic agents is to conjugate the already established activity of known anti-cancer drugs to a molecule that is vectorized into cancer cells via a selective transport system. One possibility is to exploit the polyamine transport system overactive in many tumour cells. This is the case for the anticancer drug candidate F14512 that contains a spermine chain in place of the C4 glycosidic moiety of etoposide ( Figure 1 ). The positively charged spermine tail contributes to (i) favour selective uptake of the drug by tumour cells via the polyamine transport system, (ii) increase DNA binding to reinforce topoisomerase II inhibition, (iii) enhance the water solubility of the drug. These properties promote a favourable pharmacological profile as F14512 has demonstrated potent in vitro and in vivo anti-tumour activities in preclinical studies, that overall were superior to those of etoposide, its parent compound. [8] [9] [10] [11] [12] [13] [14] Thus F14512 seems to fulfil all the requirements of an optimal polyamine drug conjugate. Furthermore, a clear correlation between the expression of the polyamine transport system system in 13 leukemia cell lines and their sensitivity to the cytotoxic action of F14512 was established. 8 On the basis of all these robust in vitro and in vivo preclinical data, F14512 was advanced to clinical development and is currently ending a Phase I clinical trial for the treatment of refractory/relapsing AML. 15 A total of 50 patients with refractory or relapsing AML were treated from January 2010 to January 2012 at 12 dose levels ranging from 1 to 44 mg/m 2 . Patients received 1 h daily intravenous infusion for five consecutive days every 2-6 weeks depending on leukemia response and recovery of sufficient hematopoiesis and resolution of toxicities. The main toxicity was myelosuppression, which was dose-dependent and reversible. The maximal tolerated dose was reached at 44 mg/m 2 and the recommended dose was determined to be 39 mg/m 2 (ref. 15) . Anti-leukemic activity was observed at different dose levels with 10% complete responses, 8% complete responses with incomplete recovery and three patients who experienced haematological improvements. The conclusion of this study was that clinical outcome of this heavily pre-treated population seemed promising.
The purpose of the present study was then to assess the in vivo preclinical activity of F14512 against a series of human AML models to further support the ongoing clinical development in onco-hematology, to identify cytotoxic agents that could potentiate F14512 activity in combination, and to examine the mechanisms of cell death triggered by F14512 in these leukemia cells.
MATERIALS AND METHODS Drugs
For in vivo studies, F14512 (Pierre Fabre Mé dicament, Castres, France), etoposide (Pierre Fabre Mé dicament) and Ara-C (Sigma-Aldrich, Saint-Quentin Fallavier, France) were dissolved in: NaCl 0.9%, a mixture of 5% dimethyl sulfoxide, 5% Tween 80 and 90% glucose serum and water, respectively. For in vitro studies, each drug was first dissolved in dimethyl sulfoxide and used in cellular assays at a maximal final dimethyl sulfoxide concentration of 0.1%.
Cell lines
KG1 (DSMZ, Braunschweig, Germany) cells were stably transfected with the firefly luciferase reporter gene and clonally selected to generate the KG1-Luc cell line. 16 HL-60 (ATCC/LGC, Molsheim, France), U-937 (ECACC, Salisbury, England) and KG1-Luc cells were grown in RPMI-1640 with 20% FBS, 100 mg/ml penicillin-streptomycin.
AML patient samples
Patient samples were collected after informed consent according to institutional guidelines, and the studies were approved by the scientific committee of the Centre de Ressources Biologiques des Hé mopathies Malignes de l'INSERM Midi-Pyré né es (Toulouse, France). The three AML patient samples, LAM-2, LAM-7 and LAM-18 used in this study exhibit a normal karyotype and FLT3-internal tandem duplication and NPMc mutations.
Cord blood cells
Cord blood was collected from mothers attending the Royal London Hospital (London, UK) after informed consent and via a protocol approved by the local Research Ethics Committees.
Mice
The various strains of homozygous female mice were used for implantation of human leukemia cells as follows: NSG mice (NOD.Cg-Prkdc
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tm1Wjl / SzJ, Charles River Laboratories, Saint-Germain-sur-L'Arbresle, France) for AML patient cells, NOD/SCID mice (NOD.CB17-Prkdc scid /J, Charles River Laboratories) for HL-60, U937 or KG1-Luc cells and SCID mice (CB17/Icr-prkdc scid /IcrCrl, Charles River Laboratories) for subcutaneous implantation of HL-60. Animals were handled and cared for in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996) and the European Directive EEC/86/609, under the supervision of authorised investigators. They were fed with standard chow.
Xenotransplantation of human AML cells into mice and in vivo chemotherapy
All experiments were conducted in compliance with French regulations and local ethical committee guidelines, as detailed previously. 17 All mice received sublethal irradiation 24 h before either intravenous or intra-tibia implantation with 1-5 Â 10 6 human AML cells. Engraftment levels of human AML cells were evaluated by quantitative real-time PCR performed from mouse blood samples or by non-invasive bioluminescence imaging (for the KG1-Luc model). Once human AML development in mice was confirmed, mice randomisation in treatment cages was performed and treatments were initiated. In each chemotherapy trial, mice were weighed at least twice weekly and checked daily, with any adverse clinical reactions noted and deaths recorded.
Cell staining and flow cytometry
For evaluation, the femurs, tibias and pelvises were dissected and flushed with HBSS. Cells were stained with human specific phycoerythrin-conjugated anti-CD45 (555483), R-phycoerythrin-conjugated anti-CD44 (555479), Phycoerythrin-Cy7-conjugated anti-CD33 (333952), FITC-conjugated anti-CD19 (555412) antibodies, or phycoerythrinconjugated anti-CD34, phycoerythrin-Cy7-conjugated anti-CD38 and PerCp-conjugated anti-CD45 antibodies (all from BD Pharmingen, San Diego, CA, USA).
CD33 þ cell population was further analyzed for apoptosis, senescence or autophagy detection. Active caspase-3 was detected in human CD33-labelled cells using FITC-conjugated anti-activated caspase-3 antibody (51-68654X, BD Biosciences, Le Pont de Claix, France), after fixation and permeabilization steps (55048BD Biosciences), according to manufacturer's instructions. For senescence detection, CD33-labelled cells were incubated 80 min with 25 mM C12-FDG (D2893, Invitrogen, Saint-Aubin, France). 18 For autophagy detection, CD33-labelled cells were fixed in 4% paraformaldehyde, permeabilized in ice-cold methanol (90%), and stained with anti-LC3B monoclonal antibody (3868S, Cell Signaling Technology, Saint Quentin Yvelines, France), followed by a Alexa Fluor 488-conjugated secondary antibody. Stained cells were analyzed using FACSAria flow cytometer and BD FACSDiva software (Becton Dickinson, Pont de Claix, France). More than 10000 DAPI negative events were collected.
Quantitative real-time PCR Engraftment levels of human AML cells in mice were assessed from blood samples taken from mouse tail vein. Genomic DNA of mouse peripheral blood was extracted using the Smart DNAdem kit, according to manufacturer's instructions (Ademtech, Pessac, France). Copy number of a human specific 479 base pair fragment of the a-satellite DNA of chromosome 17 and mouse GAPDH was assessed by standard real-time quantitative-PCR (iQ Supermix, Bio-Rad, Marne la Coquette, France). The primer sequences used were as follows: human chromosome 17,
Each gene was amplified individually and in duplicate. Relative gene copy numbers were assessed using the delta delta threshold cycle (DDC t ) method as follows:
Copy number ¼ 2 (fold change in hChr17 (AML engrafted mice/non-engrafted mice)/fold change in mGAPDH (AML engrafted mice/non-engrafted mice)) .
Immnuhistochemistry
Mouse bone specimens were fixed in 4% buffered formalin before decalcification and then dehydratation. Bones were subsequently embedded in paraffin wax and cut into 3-mm thin sections. Immunohistochemical staining was then performed using a human anti-CD45 antibody (Mob 040, Diagnostic Systems, Le Pont de Claix, France).
In vitro combination therapy HL-60 cells grown in RPMI-1640 with 10% FBS, 2 mM L-glutamine, 100 mg/ml penicillin-streptomycin and 1.25 mg/ml fungizone were seeded in 96-well plates (3 Â 10 5 cells/well), incubated for 24 h and then treated for 72 h with a combination of two test compounds under concurrent exposure conditions. Cell viability was then evaluated by dosing the ATP released by viable cells using the ATPlite assay (Perkin Elmer, Villebon sur Yvette, France). Synergistic, additive or antagonist effect was determined by the method of Chou-Talalay. F14512 also reduced the growth of KG1-Luc cells in mice KG1-Luc cells were engrafted in the tibia of mice and leukemia cell growth was monitored by bioluminescence imaging. The control group showed signs of disease progression, whereas F14512-treated mice responded to treatment in a dose-dependent manner, as reflected by a maximal inhibition of the bioluminescence signal of 94.2 and 71.7%, recorded 5 days after the end of treatment, at 0.20 and 0.125 mg/kg, respectively (Figure 3a) . The dose of 0.063 mg/kg F14512 was inactive in this model. An example of bioluminescence images is provided in Figure 3b . Furthermore, analysis of the human KG1-Luc cell content in mouse tibia bone marrow (% hCD44 þ cells) was performed 2 weeks after the end of treatment, using flow cytometry. The mean percentage of KG1-Luc cell engraftment in control mice was 64.7%, whereas it was 39.7% in the 0.20 mg/kg F14512-treated group.
Administration of F14512 did not result in any significant body weight loss or drug presumed-related death at 0.063, 0.08, 0.125 and 0.20 mg/kg, in the various models used.
The in vivo anti-leukemic effects of F14512 were then investigated against AML models established from patient samples.
F14512 extensively reduced primary AML xenografts in vivo After intermittent administrations of F14512 at 0.32 mg/kg, an extensive reduction of AML cell number was observed in the bone marrow of LAM-2 and LAM-7-bearing mice (Figures 4a and b) , as reflected by percentages of inhibition of 99.1 and 99.8% for LAM-2 and LAM-7, respectively. F14512 also induced a reduction of LAM-18 cell number in mouse bone marrow, as reflected by a value of human AML cell number inhibition of 83% at 0.32 mg/kg (Figures 4a and b) . F14512 was also assessed at 0.20 mg/kg in this LAM-18 model and has shown a significant anti-leukemic activity, with a 50% inhibition of human AML cell number.
The immunohistochemical analyses confirmed the development of human AML within NSG mice bone marrow and its marked inhibition by F14512 (Figure 4c ). To complete these bone marrow analyses, we quantified by qPCR the number of circulating human leukemic cells in mouse blood (only for LAM-2 and LAM-18 models as LAM-7 cells proliferate mainly in mouse bone marrow) (Figure 4d ). The effects of F14512 on circulating human AML cells in mouse blood were potent and rapid as they were already observed 24 h after the first administration.
F14512 treatments were well tolerated by LAM-2, LAM-7 and LAM-18 engrafted NSG mice as administration of F14512 did not result in any significant weight loss or presumed drug-related deaths, when given intravenous at 0.32 or 0.20 mg/kg, using multiple intravenous intermittent injections over 3 weeks.
Enhanced anti-leukemic activity of F14512 in combination with cytosine arabinoside (Ara-C) F14512 demonstrated an in vitro synergism in combination with the DNA damaging agents Ara-C, doxorubicin or gemcitabine, with the HDAC inhibitor, SAHA or with the proteasome inhibitor, bortezomib. Etoposide and the tubulin-interacting agents paclitaxel and vinorelbine resulted in additive effects when combined to F14512, whereas the combination of topoisomerase I inhibitor camptothecin and F14512 induced antagonist effects ( Table 1 ). The effects of F14512 in combination with Ara-C, each given at suboptimal doses, were further investigated in vivo using the intravenously implanted LAM-2 (primary AML) and the subcutaneously-HL-60 models. Enhanced antileukemic activity was observed against the LAM-2 model, when 0.063 mg/kg F14512 was combined with 7.5 mg/kg Ara-C. This combination triggered a marked decrease of the human leukemic cell number in mouse bone marrow (Figure 5a ). Intermittent administrations of 0.125 mg/kg F14512 combined with daily administrations of 30 mg/kg Ara-C resulted in enhanced anti-leukemic activity against HL-60 tumours compared with single compound administration, as reflected by an overall tumour growth inhibition of 46, 89 and 95.3% after treatment with Ara-C, F14512 or the combination, respectively (Figure 5b ). Furthermore the combination of F14512 with Ara-C resulted in 100% HL-60 tumour regressions, whereas no tumour regression was obtained after Ara-C treatment, and only 2/5 tumour regressions were recorded after F14512 treatment. It should be noted that the subcutaneously implanted HL-60 model was less sensitive to Ara-C than the model of intravenously implanted LAM-2 primary AML cells, A total of 10 6 KG1-Luc cells were implanted in the tibia of sublethally irradiated NOD/SCID mice on day zero. On day 6, F14512 was given intravenous at the indicated doses, according to the q2d3 schedule over 3 weeks. (a) Evolution of the bioluminescence signal for control and F14512-treated groups. Animals were peritoneally injected with 125 mg/kg luciferin potassium salt (Caliper Life Sciences, Roissy, France) before undergoing anesthesia with 3% isoflurane in air in an anesthesia induction box. Then 2% isoflurane in air/O 2 was continuously delivered via a nose cone system in the dark box of a high sensitivity CCD camera (Berthold, Thoiry, France). Bioluminescence imaging was performed 10 min after substrate injection. Effects of F14512 on primary cord blood progenitor cells The results showed that F14512 impeded the formation of normal progenitor colonies by 83 and 100% at 10 and 100 nM, respectively, whereas no significant effect was observed at 1 nM (Figure 6a ). Then the effects of F14512 on the growth of normal hematopoietic cells in vivo were investigated using xenografts derived from human cord blood Lin À cells. F14512 reduced the general engraftment level by 48% and 86.4% at 0.125 and 0.20 mg/kg, respectively (Figure 6b ). However, the respective percentage of CD34 þ CD38 À , CD34 þ CD38 þ , CD45 þ CD19 þ and CD45 þ CD33 þ were not significantly affected (Figure 6c ).
The in vivo anti-leukemic activity of F14512 was mediated through senescence and apoptotis cell death mechanisms LAM-2-, LAM-7-and LAM-18-bearing mice were treated with F14512 and cell death induction was measured ex vivo in human leukemic cells extracted from mouse bone marrow, 24 h (D1) and Novel polyamine conjugate antileukemic activity A Kruczynski et al 7 days (D7) after the last treatment. Results showed that F14512 in vivo treatments induced both apoptosis and senescence mechanisms in LAM-2, LAM-7 and LAM-18 cells (Figure 7a) . Induction of apoptosis is reflected by maximal fold increases, relative to control values of 9.5, 37.1 and 2.9 for LAM-2, LAM-7 and LAM-18, respectively, and senescence induction is represented by maximal fold increase of 32.3, 45 and 4.4 for LAM-2, LAM-7 and LAM-18, respectively. In sharp contrast, no autophagy was observed in leukemic cells from F14512-treated mice (data not shown). Furthermore, the level of mRNA transcripts of 41 genes known to be involved in apoptosis, senescence or autophagy pathways were assessed ex vivo by quantitative PCR in these same human leukemic cell samples extracted from bone marrow of control and F14512-treated mice. The results showed that F14512 treatments were accompanied by an upregulation of cyclin D1 (CCND1), the cyclin-dependent kinase inhibitor p21 (CDKN1A), as well as of the proapoptotic regulators BAX and BCL2L11 (Figure 7b) .
DISCUSSION
This study documents the potent in vivo activity of F14512 against models of human AML, alone or in combination with Ara-C. Furthermore we show that this antileukemic activity might be mediated through both apoptosis and senescence mechanisms. LAM-2 cells were implanted intravenous on sublethally irradiated NSG mice on day zero. On week 6, F14512 and Ara-C alone or in combination were given intraperitoneal at the indicated doses, according to the (q2d3) Â 3 weeks and q1d5 schedules, respectively. Assessment of human leukemic cells (%CD45 þ /CD33 þ ) in mouse bone marrow was performed using flow cytometry, on week 8 after leukemic cell implantation. (b) F14512 and Ara-C combination efficacy in HL-60 xenografted tumors. A total of 3 Â 10 6 HL-60 cells were implanted subcutaneously on SCID mice on day zero. When tumors had reached a volume of 100-150 mm 3 on day 21, mice are randomized and F14512 and Ara-C alone or in combination were given intraperitoneal, at the indicated doses, over 2 weeks, according to the q2d3 and q1d5 schedules, respectively. Tumors were measured with callipers and tumor volumes (mm 3 ) are estimated as 0.5 (length Â width 2 ). Experiments involved five to six mice per experimental group.
Novel polyamine conjugate antileukemic activity A Kruczynski et al F14512 was designed with the goal to combine the potent cytotoxic properties of epipodophyllotoxin derivatives and a vectorization to cancer cells via a polyamine chain. Initial studies have already demonstrated superior in vivo antitumor activity, of this polyamine conjugate, in comparison to etoposide, its nonvectorized parent compound, with a wider therapeutic index, using the MX-1 human breast tumour model. 10 Indeed F14512 induced also a higher response rate of 67% in a large series of experimental tumour models, with activities obtained at several dose levels without severe toxic side effects. 13 The in vivo antileukemic activity was investigated here for the first time. F14512 had a marked effect on the growth of various AML cells, including primary AML cells from patient samples. More specifically, F14512 resulted in a high level of activity in all the models analyzed. Of course, further investigations will be needed to assess whether the few residual leukemic cells still present after F14512 treatment are able or not to re-establish the leukemia. F14512 also clearly showed a superior in vivo activity to etoposide against the HL-60 model. These data again illustrate the benefit provided by the preferential delivery of drugs to tumour cells. 8 Etoposide induced only a marginal activity against the HL-60 tumours at 12.5 mg/kg but the administration of a higher dose is not possible because of severe toxic side effects. Indeed at 20 mg/kg etoposide treatments result in both relative body weight losses higher than 20% and early deaths (data not shown), which is considered highly toxic according to National Cancer Institute criteria. 20 F14512 had some effects on normal cord blood Lin À cells, like almost all the anti-leukemic agents used in clinic, including the most recent ones, such as vosaroxin. 21 However, again F14512 was well tolerated by the tumour-bearing mice, used in our pharmacological studies. This was observed in terms of mouse body weight and clinical signs. Therefore, we suggest that the effects on leukemia cells might be more pronounced than those on normal progenitor cells. Furthermore, preliminary results of the Phase I clinical trial, including patients with relapsed or refractory AML are encouraging, with antileukemic activity shown at different dose levels and data indicating that F14512 appears to be well tolerated. 15 The FLT3 receptor is mutated in about a third of AML patients, the most frequent genetic alteration being an internal tandem duplication of exons 14 and 15. 22 Clinically, patients with FLT3-internal tandem duplication mutated AML have a higher rate of relapse, a shorter disease-free survival and a shorter overall survival than patients with wild-type FLT3 AML. 23 F14512 was shown to be a highly effective inhibitor of the in vivo growth of LAM-2, LAM-7 and LAM-18 cells that all three exhibit a Mechanisms of resistance are a major limitation of the efficacy of chemotherapeutic agents in clinic. P-glycoprotein-mediated drug efflux is a well-characterized tumour resistance mechanism. Preliminary in vitro data suggest that F14512 is neither a substrate nor an inhibitor of P-glycoprotein (data not shown). These results need now to be confirmed in vivo. If confirmed this property could allow an enlarged clinical use of F14512.
Synergy between F14512 and Ara-C was observed in vitro under concurrent exposure conditions. Furthermore the combination of low doses of F14512 with Ara-C resulted in increased in vivo antileukemic activity. Additional experiments will explore the optimal combination therapy mainly to define an administration Ex vivo analysis of apoptosis and senescence using flow cytometry. A total of 2 Â 10 6 LAM-2, LAM-7 or LAM-18 cells were implanted intravenous on sublethally-irradiated NSG mice on day zero. Seven weeks after LAM-2 cell implantation and 11 weeks after LAM-7 or LAM-18 cell implantation, F14512 was given intraperitoneal at 0.63 mg/kg over 2 weeks according to the q2d3 schedule. A higher dose of F14512 was given in order to increase the cell death signals to allow an easier detection. This dose did not result in any adverse effects during the experiment. Twenty-four hours (D1) and 7 days (D7) after the last treatment, cell death induction was measured ex vivo in human leukemic cells extracted from mouse bone marrow. Induction of apoptosis was assessed by measuring caspase-3 activity, senescence induction was evaluated using the fluorescent probe C12-FDG that releases fluorescein when hydrolyzed by SA-b-Gal. For autophagy detection, the lipid-conjugated form of MAP-LC3 (LC3-II) that localizes on the membrane of auto-phagosomes was used. (b) Evaluation of the mRNA level of 41 genes, known to be involved in apoptosis, senescence or autophagy pathways, after in vivo treatment of human leukemic cells with F14512. After the extraction of human leukemic cells from bone marrow of LAM-2 or LAM-7 or LAM-18-bearing mice, and RNA purification using RNAeasy (Qiagen, Courtaboeuf, France), the quantitation of each transcript was assessed with SyBr green detection using the DDC t parameter calculated with the RQ (Relative Quantification) software (Applied Biosystem, Villebon sur Yvette, France). Two independent in vivo experiments were performed with the LAM-2 and LAM-7 models and one in vivo experiment was performed with the LAM-18 model. Each experiment included three mice per experimental group (control or treated). Amongst those experiments, the genes induced the most frequently and at the highest level (at least twofold increase) were represented.
sequence and schedule for clinical use. More specifically, it has been shown that Ara-C pretreatment of CEM cells (human lymphoblastoid cells) before their treatment with etoposide resulted in an increase in both the cytotoxic and the DNAdamaging effects of etoposide. This may be due to the observed Ara-C-induced synchronization of cells in S phase. 24 Synergy was also observed in vitro between F14512 and doxorubicin, another DNA-damaging agent belonging of the same pharmacological class as the one used for the treatment of AML. Many agents are currently under investigation for induction chemotherapy of newly diagnosed AML or reinduction treatment of relapsed or refractory disease. Bortezomib, the proteasome inhibitor and histone deacetylase inhibitors are two of these compounds.
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F14512 demonstrated also in vitro synergistic effects when combined with bortezomib or SAHA, which suggests, if confirmed, another potential clinical application of F14512.
This study also provides additional information to better understand the mechanism of action of F14512 in leukemic cells. We demonstrated that F14512 triggered both senescence and apoptosis in vivo in leukemia cells but not autophagy. Senescence along with mitotic catastrophe and apoptosis, is a major antiproliferative effect and a determinant of the long-term success of cancer therapy. 26 Apoptosis and senescence are mechanisms of action already well described for DNA damaging agents, including topoisomerase inhibitors. [27] [28] [29] [30] 26 Indeed amongst different classes of anticancer agents, the senescent phenotype is induced most strongly by agents that affect DNA structure, such as doxorubicin, cisplatin, ionizing radiation, Ara-C and etoposide. 26 Senescence has been previously described as the preferential mechanism induced by F14512 in A549 (NSCLC) cells. 11 More specifically, F14512 triggered apoptosis only at high concentrations in these cells, whereas it induced senescence at pharmacological doses corresponding to IC 50 value for anti-proliferative activity.
11 Using P388 murine leukemia cells, Ballot et al. 7 also showed that the activation of the DNA damage response by F14512 did not induce immediate apoptosis but resulted in an early growth arrest associated with a senescence-like phenotype. In our case, a more detailed kinetic study should be required to determine whether senescence and then delayed apoptosis occur in the same cells or whether these mechanisms occur in different cell populations. It is noticeable that overall the maximal in vivo anti-tumour efficacy of F14512 was not seen during the treatment but rather at the end of treatment or even though 1 week or more after the end of treatment (as it is the case in the present study), and the strong and irreversible impact of F14512 on cell proliferation was associated with a delayed cell death. 9, 11, 13 It has been shown that despite a potent cytotoxic activity and a prominent inhibition of topoisomerase II, F14512 induced much less DNA damage or less detectable than its parent compound etoposide. 9, 11 Furthermore data from Chelouah et al., 14 suggest that F14512 has the unique ability, over some other topoisomerase II poisons, to interact with specific DNA targets. Therefore, we could hypothesize that the DNA damages induced by F14512 are not easily repaired, which would be consistent with a delayed cell death. The DNA repair pathway activated by F14512 remains to be elucidated to confirm this hypothesis.
Concomitant with senescence and apoptosis detection, increased expression of cyclin D1, p21 and the apoptosis inducers BAX and BCL2L11 were observed ex vivo in the primary LAM-2, LAM-7 and LAM-18 cells. Ballot et al. 9 also showed that F14512 induced-senescence in P388 cells was associated with an upregulation of p16 and cyclin D1. Several cyclin-dependent kinase inhibitors, such as p21, p16 and p15 have been described as regulators of senescence in tumour cells. 26, 30, 31 However it is important to bear in mind that these cell cycle related genes are also involved in apoptosis regulation. It exists clear relationships between DNA damage-induced senescence and apoptosis. It is still unclear what determines the choice between apoptosis and senescence, but determinants may include cell type, the intensity, duration and nature of the damage. Ballot et al. 9 identified survivin as the molecular determinant responsible for a qualitative shift in P388 cell fate from senescence to apoptosis upon treatment with F14512. The complexity of these relationships explains why changes in identified genes could have different effects on tumour response to treatment in different cellular contexts.
Overall, the results of this present study clearly demonstrate that F14512 is able to trigger both senescence and apoptosis in leukemic cells, which could represent an advantage for the clinical use of F14512, especially in apoptosis-refractory tumours. To further enhance its clinical benefit, it might be also worth combining F14512 with autophagy modifiers. 32, 33 Collectively, these results show that F14512, a sperminevectorized potent anticancer agent exhibits a marked in vivo antileukemic activity alone or in combination with Ara-C, and is capable of inducing both apoptotic and senescence-type pathways. This therefore supports its clinical development. Phase I clinical trials in onco-hematology are ending and Phase II studies are planned with this novel promising drug candidate.
